Clinical ResourcesAdolescent Depression Module by the University of Nebraska Medical Center
Program Goal: To provide a practical course on the diagnosis and treatment of adolescent depression for health care practitioners providing front line care to patients.
- Describe the hallmark signs and symptoms of adolescent depression
- Identify the best practice guidelines for antidepressant use in adolescent depression
- Recognize key risk factors associated with adolescent suicide
- Evaluate the role of cognitive behavioral therapy in the treatment of adolescent depression
HFS has added 3 long/intermediate-acting stimulants (all of them are methylphenidate products) to its Preferred Drug List (PDL) as of Oct 1, 2011. The new medications are boldfaced and in red at the bottom of page 14 in the attached PDF/a> :
amphetamine salts +
Since April of 2011, methylphenidate SR had been the only long/intermediate-acting stimulant on the PDL. The bad news is that Ritalin SR, methylphenidate SR, Methylin ER, and Metadate ER are the same formulation and have the same drug delivery system, which has some evidence showing that it is a suboptimal delivery system. There is no component that is immediate-release and many children may need an immediate-release dose in the morning to cover symptoms. The morning dose can be taken with the long-acting dose or 60-90 minutes before the Ritalin SR, methylphenidate SR, Methylin ER, and Metadate ER is given. Another potential and frequently reported problem with these medications is that coverage of symptoms has a highly variable duration. Duration is supposed to be 6-8 hours. Many clinicians also report that a number of patients taking these medications seem to require more medication on average compared with other long/intermediate-acting methylphenidate products. The good news is that, whereas Ritalin SR only comes in a 20 mg sized tablet, Methylin ER and Metadate ER come in 10 mg and 20 mg sized tablets.
For more information and consultation please call DocAssist, 1-866-986-ASST (2778) or visit us at www.psych.uic.edu/docassist.
Mental Health and Substance Abuse Tools:
DocAssist Recommended Screening Tools
Illinois DocAssist recommends three (3) general screening tools, one (1) ADHD and (1) Bipolar screening tool and seven (7) depression screening tools for use by primary care providers. Some tools have a cost associated with their use but most are free and accessible via the links in the chart . These instruments assist in the early identification of problematic behaviors and social-emotional functioning that may indicate the need for further evaluation.
Provider Reimbursement for Child and Adolescent Mental Health and Substance Abuse Screening: The Illinois Department of Healthcare and Family Services (IDHFS) will only reimburse for child and adolescent mental health and substance abuse screening using approved tools. To access additional information about IDHFS approved screening tools please click here.
Suicide Risk Assessment Charting Tool:
A PCP/user-friendly tool to assist in assessing the risk of suicidality in adolescents. This resource is not intended to take the place of any discussions with the patient. All suicide assessments need to be conducted directly from clinician to patient.
AACAP Practice Parameters
Practice Parameters are descriptions of generally accepted practices printed in the Journal of the American Academy of Child and Adolescent Psychiatry. Some of the Practice Parameters are listed below. For more information on the AACAP Practice Parameters, please visit http://aacap.org/cs/root/member_information/practice_information/practice_parameters/practice_parameters/
“Facts for Families”
Looking for information on some of the serious issues that affect children, teenagers, and their families such as depression, attention deficit hyperactivity disorder, and substance abuse? The American Academy of Child and Adolescent Psychiatry provides information on these topics and more on their website under “Facts for Families”.